Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist

<p>Abstract</p> <p>Pharmacodynamic assays are important in clinical trial design to investigate the relationship between drug concentration (pharmacokinetics) and drug "effect' or biological activity. Increasingly flow cytometry is being used to examine the pharmacodynami...

Full description

Bibliographic Details
Main Authors: Lackey Alan, Wyant Timothy, Green Marie
Format: Article
Language:English
Published: BMC 2008-12-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/6/1/76
id doaj-543e11d33b0b4285ae47e1b09275defe
record_format Article
spelling doaj-543e11d33b0b4285ae47e1b09275defe2020-11-24T21:44:35ZengBMCJournal of Translational Medicine1479-58762008-12-01617610.1186/1479-5876-6-76Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonistLackey AlanWyant TimothyGreen Marie<p>Abstract</p> <p>Pharmacodynamic assays are important in clinical trial design to investigate the relationship between drug concentration (pharmacokinetics) and drug "effect' or biological activity. Increasingly flow cytometry is being used to examine the pharmacodynamic effect of new drug entities. However, to date, the analytical validation of cytometry based assays is limited and there is no suitable guidance for method validation of flow cytometry-based pharmacodynamic assays. Here we report the validation of a flow cytometry-based chemokine internalization assay for use in evaluating the effect of a receptor antagonist in clinical trials. The assay method was validated by examining the stability of the reagent, assay robustness, sensitivity, repeatability and reproducibility precision. Experimental results show the assay reagent was stable over 26 weeks. The assay demonstrated a sensitivity to distinguish 0.005 μg/ml of a CCR2 antagonist with a %CV of 13.3%. The intra-assay repeatability was less than 15% with an inter-assay repeatability of less than 20%. In vivo study results demonstrated that the assay was consistent and a reliable measure of antagonist activity.</p> http://www.translational-medicine.com/content/6/1/76
collection DOAJ
language English
format Article
sources DOAJ
author Lackey Alan
Wyant Timothy
Green Marie
spellingShingle Lackey Alan
Wyant Timothy
Green Marie
Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist
Journal of Translational Medicine
author_facet Lackey Alan
Wyant Timothy
Green Marie
author_sort Lackey Alan
title Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist
title_short Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist
title_full Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist
title_fullStr Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist
title_full_unstemmed Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist
title_sort validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist
publisher BMC
series Journal of Translational Medicine
issn 1479-5876
publishDate 2008-12-01
description <p>Abstract</p> <p>Pharmacodynamic assays are important in clinical trial design to investigate the relationship between drug concentration (pharmacokinetics) and drug "effect' or biological activity. Increasingly flow cytometry is being used to examine the pharmacodynamic effect of new drug entities. However, to date, the analytical validation of cytometry based assays is limited and there is no suitable guidance for method validation of flow cytometry-based pharmacodynamic assays. Here we report the validation of a flow cytometry-based chemokine internalization assay for use in evaluating the effect of a receptor antagonist in clinical trials. The assay method was validated by examining the stability of the reagent, assay robustness, sensitivity, repeatability and reproducibility precision. Experimental results show the assay reagent was stable over 26 weeks. The assay demonstrated a sensitivity to distinguish 0.005 μg/ml of a CCR2 antagonist with a %CV of 13.3%. The intra-assay repeatability was less than 15% with an inter-assay repeatability of less than 20%. In vivo study results demonstrated that the assay was consistent and a reliable measure of antagonist activity.</p>
url http://www.translational-medicine.com/content/6/1/76
work_keys_str_mv AT lackeyalan validationofaflowcytometrybasedchemokineinternalizationassayforuseinevaluatingthepharmacodynamicresponsetoareceptorantagonist
AT wyanttimothy validationofaflowcytometrybasedchemokineinternalizationassayforuseinevaluatingthepharmacodynamicresponsetoareceptorantagonist
AT greenmarie validationofaflowcytometrybasedchemokineinternalizationassayforuseinevaluatingthepharmacodynamicresponsetoareceptorantagonist
_version_ 1725909244203499520